Posted 29 September 2021
BioMelbourne Network member Cancer Therapeutics (CTx CRC Ltd) has unveiled its new name and brand identity – Canthera Discovery.
This transformation forms part of a wider organisational strategy to continue the incredible legacy of the Cancer Therapeutics CRC and cement the Company’s position as a leader in Australia’s cancer drug discovery and development ecosystem.
As Canthera Discovery, the organisation’s focus will be to continue to grow its national collaborative network of research organisations – which include Australia’s leading research institutes, universities and biotech firms – to translate the latest research into new treatments that address unmet needs in the oncology space.
Canthera Discovery Managing Director, Dr Alan Robertson said:
“Since the wind up of the Cancer Therapeutics CRC in 2020, our organisation has been working hard to develop a plan for the future, to ensure that we can continue the important translational research collaborations that have been critical to the success of the CRC.”
Established in 2007, the Cancer Therapeutics CRC oversaw over 30 research projects, and led numerous initiatives to progress cancer therapeutics research in Australia. Key successes include multiple licensing deals of pre-clinical assets, more than $50M in license revenue, two drugs currently in clinical trials, and the establishment of new Australian biotech entities. Other notable contributions to the sector include leading the consortium that established the Australian Drug Discovery Library, a curated small molecule library to enhance Australian research, as well as providing seed funding for the ‘Zero Childhood Cancer’ program launched by the Children’s Cancer Institute (CCI) and The Sydney Children’s Hospitals Network in 2015. Canthera Discovery aims to build upon this legacy, and in collaboration with our partners continue to make a tangible difference to the lives of cancer patients.
Canthera Discovery Managing Director, Dr Alan Robertson said:
“We are excited about what the future holds for Canthera Discovery, as we believe that this new identity will strengthen our position as a world-class research organisation and set the scene for continuing the valuable work we undertake with our partners in finding cures for cancer.”
